## **Nectar Lifesciences Ltd.**



Ref No. NLL/CS/2023-263

May 26, 2023

To

National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai 400 051 Symbol: NECLIFE

BSE Limited Corporate Relationship Department, P J Towers, Dalal Street, Mumbai 400 001 Scrip Code: 532649

**Sub:** Disclosure of Related Party Transactions.

Ref.: SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021

Dear Sir/Madam,

Pursuant to Compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and captioned circular, please find enclosed the disclosure on Related Party Transactions for half year period from October 01, 2022, to March 31, 2023.

This is for your information and records.

Yours faithfully,

For Nectar Lifesciences Limited

(Neha Vaishnav)

Company Secretary & Compliance Officer

Encl. As above

## FOR HALF YEAR ENDED ON MARCH 31, 2023

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/ subsidiary. Theses details need to be disclosed only once, during the reporting period when such transaction was undertaken.

											reporting period when such transaction was undertaken.									
S. No.	Details of the party (listed entity/ subsidiary) entering into the transaction  Name PAN Name PAN Relationship of					Type of related party transactions	Value of the related party transaction as approved by the audit	Remarks on approval by Audit Committee	Value of transactio n during the reporting	a result of the transaction		In case any financial indebtness is incurred to make or give loans, inter- corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments					
															Nature (loan/ advance/	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilized by the	
					the counterparty with the listed entity orits subsidiary		committee		period	Opening Balance	Closing Balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	inter- corporate deposit/ invesment				ultimate recipient of funds (end- usage)	
1	Nectar Lifesciences Limited		Mr. Sanjiv Goyal		Chairman & Managing Director	Managerial Remuneration	Note 1	Note 1	102.28	3.15	3.69	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
2	Nectar Lifesciences Limited		Mr. Puneet Sud		Wholetime Director	Managerial Remuneration	Note 1	Note 1	34.13	0.68	9.10	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
3	Nectar Lifesciences Limited		Mr. Amit Chadah		Chief Executive Officer	Salary to KMP	Note 1	Note 1	38.63	3.19	7.23	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
4	Nectar Lifesciences Limited		Mr. Sandeep Goel		Chief Financial Officer	Salary to KMP	Note 1	Note 1	21.30	1.68	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
5	Nectar Lifesciences Limited		Mr. Sushil Kapoor		Chief Financial Officer	Salary to KMP	Note 1	Note 1	6.85	-	1.30	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
6	Nectar Lifesciences Limited		Ms. Anubha		Company Secretary	Salary to KMP	Note 1	Note 1	0.68	0.35	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
7	Nectar Lifesciences Limited		Ms. Neha Vaishnav		Company Secretary	Salary to KMP	Note 1	Note 1	0.46	-	0.27	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
8	Nectar Lifesciences Limited		Mr. Ajay Swaroop		Independent Director	Sitting Fees	Note 1	Note 1	0.25	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
9	Nectar Lifesciences Limited		Dr. Rupinder Tewari		Independent Director	Sitting Fees	Note 1	Note 1	0.60	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
10	Nectar Lifesciences Limited		Dr. Kuldip Kumar Bhasin		Independent Director	Sitting Fees	Note 1	Note 1	0.60	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
11	Nectar Lifesciences Limited		Ms. Meena Verma		Nominee Director	Sitting Fees	Note 1	Note 1	0.40	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
12		1	Mrs. Indu Pal Kaur		Independent Director	Sitting Fees	Note 1	Note 1	0.50	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
13	Nectar Lifesciences Limited		Nectar Lifesciences Charitable Foundation		Promoter/Direc tor and KMPs have significant Influence	CSR expenditure	Note 1	Note 1	10.96	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
14	Nectar Lifesciences Limited		Nectar Lifesciences USA LLC		Wholly owned subsidiary	Purchase/ Sale/ Trade receivables/ Payable etc.	Not Applicable	Not Applicable	-	94.24	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
15	Nectar Lifesciences Limited		Nectar Lifesciences USA LLC		Wholly owned subsidiary	Investment realised	Note 2	Not Applicable	33.02	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
16	Nectar Lifesciences Limited		Mr. Amit Chadah		Chief Executive Officer	Unsecured Interest free Ioan given	Not Applicable	Not Applicable	-	30.62	30.62	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	

17	Nectar Lifesciences Limited	Sanjiv (HUF)	Promoter/Direc	Unsecured	Not	Not	-	1,000.00	1,000.00	N.A.							
			tor have	Interest free	Applicable	Applicable											
			significant	loan received													
			Influence														
18	Nectar Lifesciences Limited	Mr. Sanjiv Goyal	Chairman &	Unsecured	Note 3	Not	300.00	-	300.00	N.A.							
			Managing	Interest free		Applicable											
			Director	loan received													
19	Nectar Lifesciences Limited	Mrs. Raman	Relative of	Rent	42.00	No	42.00	-	-	N.A.							
		Goyal	Chairman &														
			Managing														
			Director														

Note 1. Audit Committee approval has been received on all perpetual transactions for the term of Managerial Remuneration/ Salary to KMPs/ Sitting Fee/ CSR Expenditure. Further approvals from Board / members have been received as per the provisions of the Companies Act, 2013

Note 2. Transaction by way of operation of law as Nectar Lifesciences USA LLC, a wholly owned subsidiary is dissolved.

Note 3. Unsecured Interest free loan received as an obligation from the promoter as per the One time restructuring with Banks in FY 2021-22, already approved by the Board of Directors. There is no resource has been transferred or proposed to be transferred from the Company.

Note 4. Opening and closing balance of Investment in subsidiaries during the half year ended March 31, 2023 are not given where there was no transaction.

For Nectar Lifesciences Limited

Date: 26-05-2023 (Sushil Kapoor)
Place: Chandigarh Chief Financial Officer